These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33319212)

  • 1. Dual targeting of 3CL
    Rajpoot S; Alagumuthu M; Baig MS
    Curr Res Struct Biol; 2021; 3():9-18. PubMed ID: 33319212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Phytochemicals from Arabian Peninsula Medicinal Plants as Strong Binders to SARS-CoV-2 Proteases (3CL
    Saquib Q; Bakheit AH; Ahmed S; Ansari SM; Al-Salem AM; Al-Khedhairy AA
    Molecules; 2024 Feb; 29(5):. PubMed ID: 38474509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme.
    Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K
    J King Saud Univ Sci; 2020 Sep; 32(6):2845-2853. PubMed ID: 32837113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
    Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
    Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
    Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
    Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyphenolic Compounds Isolated from Marine Algae Attenuate the Replication of SARS-CoV-2 in the Host Cell through a Multi-Target Approach of 3CL
    Nagahawatta DP; Liyanage NM; Je JG; Jayawardhana HHACK; Jayawardena TU; Jeong SH; Kwon HJ; Choi CS; Jeon YJ
    Mar Drugs; 2022 Dec; 20(12):. PubMed ID: 36547933
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Tronco Pauletto PJ; Omage FB; Delgado CP; Nogara PA; Teixeira Rocha JB
    Curr Drug Discov Technol; 2023; 20(2):e101022209771. PubMed ID: 36221883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 replication and drug discovery.
    Nazir F; John Kombe Kombe A; Khalid Z; Bibi S; Zhang H; Wu S; Jin T
    Mol Cell Probes; 2024 Jul; 77():101973. PubMed ID: 39025272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.
    Kuo CJ; Chao TL; Kao HC; Tsai YM; Liu YK; Wang LH; Hsieh MC; Chang SY; Liang PH
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.
    Meyer-Almes FJ
    Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL
    Bhowmik D; Sharma RD; Prakash A; Kumar D
    J Mol Struct; 2021 Jun; 1233():130094. PubMed ID: 33612858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bioactive compounds of Jingfang Granules against SARS-CoV-2 virus proteases 3CL
    Shang ZP; Yi Y; Yu R; Fan JJ; Huang YX; Qiao X; Ye M
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):907-919. PubMed ID: 36241233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses.
    Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L
    Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
    Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
    J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Products with Tandem Anti-inflammatory, Immunomodulatory and Anti-SARS-CoV/2 Effects: A Drug Discovery Perspective against SARS-CoV-2.
    da Cunha LNOL; Tizziani T; Souza GB; Moreira MA; Neto JSS; Dos Santos CVD; de Carvalho MG; Dalmarco EM; Turqueti LB; Scotti MT; Scotti L; de Assis FF; Braga AL; Sandjo LP
    Curr Med Chem; 2022; 29(14):2530-2564. PubMed ID: 34313197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV.
    Park JY; Ko JA; Kim DW; Kim YM; Kwon HJ; Jeong HJ; Kim CY; Park KH; Lee WS; Ryu YB
    J Enzyme Inhib Med Chem; 2016; 31(1):23-30. PubMed ID: 25683083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor.
    Ma C; Hu Y; Wang Y; Choza J; Wang J
    ACS Infect Dis; 2022 May; 8(5):1022-1030. PubMed ID: 35404564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Patent Review on SARS Coronavirus Papain-Like Protease (PL
    Brian Chia CS; Pheng Lim S
    ChemMedChem; 2023 Aug; 18(16):e202300216. PubMed ID: 37248169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.